Fmr LLC Grows Stake in Seres Therapeutics, Inc. (NASDAQ:MCRB)

Fmr LLC grew its position in Seres Therapeutics, Inc. (NASDAQ:MCRB) by 0.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,857,260 shares of the biotechnology company’s stock after buying an additional 140,096 shares during the quarter. Fmr LLC owned 0.13% of Seres Therapeutics worth $21,625,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in MCRB. Providence Wealth Advisors LLC raised its holdings in shares of Seres Therapeutics by 49.5% in the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 25,250 shares in the last quarter. Point72 DIFC Ltd purchased a new position in Seres Therapeutics during the 2nd quarter valued at about $64,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Seres Therapeutics during the 2nd quarter valued at about $92,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Seres Therapeutics by 42.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock valued at $708,000 after purchasing an additional 222,771 shares in the last quarter. Finally, Vontobel Holding Ltd. purchased a new stake in shares of Seres Therapeutics in the 3rd quarter worth approximately $374,000. Institutional investors own 59.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on MCRB. Canaccord Genuity Group reissued a “buy” rating and issued a $10.00 price target on shares of Seres Therapeutics in a research report on Thursday, November 14th. StockNews.com downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 27th. JPMorgan Chase & Co. downgraded Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Thursday, October 24th. Finally, Chardan Capital reissued a “buy” rating and issued a $1.25 price objective on shares of Seres Therapeutics in a research report on Wednesday, November 13th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Seres Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $5.08.

Seres Therapeutics Stock Up 3.9 %

MCRB opened at $0.86 on Tuesday. Seres Therapeutics, Inc. has a twelve month low of $0.54 and a twelve month high of $2.05. The company has a market cap of $146.00 million, a PE ratio of -3.72 and a beta of 2.07. The company has a 50-day moving average price of $0.79 and a 200 day moving average price of $0.90.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.